AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook AVITA Medical ®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced unaudited preliminary financial results and a business update for the fourth quarter and fiscal

#RCEL AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA® Medical Reports Third Quarter 2025 Financial Results AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the third quarter ended September 30,

#RCEL AVITA® Medical Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/RCEL/avita-medical-...

#RCEL Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment

www.stocktitan.net/news/RCEL/data-presented...

AVITA Medical to Announce Third Quarter 2025 Financial Results AVITA Medical (NASDAQ: RCEL) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. Pacific Time (Friday, November 7, 2025 at 8:30 a.m. Australian Eastern Daylight Time) to discuss results and recent business highlights.The live webcast will be available in the Events & Presentations section of AVITA Medical's investor website at ir.avitamedical.com. Telephone participants must register in advance to receive dial-in details and a personal PIN; a replay will be posted on the investor site shortly after the live event.

#RCEL AVITA Medical to Announce Third Quarter 2025 Financial Results

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Welcomes Support for RECELL® in Burns in Australia AVITA Medical (NASDAQ: RCEL) announced that Australia’s Medical Services Advisory Committee (MSAC) recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension (ASCS) prepared with RECELL for severe acute burn wounds in adults and children.MSAC concluded RECELL is as safe and effective as traditional autologous skin grafting and noted benefits including donor site sparing, reduced need for additional grafting, shorter hospital stays, less pain, and minimized scarring. Recommended uses include adults with ≥20% TBSA, pediatrics with ≥10% TBSA, and whole-of-face closure.

#RCEL AVITA Medical Welcomes Support for RECELL® in Burns in Australia

www.stocktitan.net/news/RCEL/avita-medical-...

Investors Under Scrutiny: Pomerantz Law Firm Probes AVITA Medical Allegations Pomerantz Law Firm is investigating allegations against AVITA Medical, Inc. following significant stock price drops. Investors advised to connect.

Investors Under Scrutiny: Pomerantz Law Firm Probes AVITA Medical Allegations #USA #New_York #Pomerantz_Law #AVITA_Medical #RCEL

Ongoing Investigation for Investors of AVITA Medical, Inc. - Key Insights The Pomerantz Law Firm is probing into allegations of securities fraud involving AVITA Medical, following significant financial setbacks.

Ongoing Investigation for Investors of AVITA Medical, Inc. - Key Insights #United_States #New_York #Pomerantz_LLP #AVITA_Medical #RCEL

AVITA Medical Announces CEO Transition AVITA Medical (NASDAQ: RCEL) announced an immediate CEO transition: Board Chairman Cary Vance is named Interim CEO and will remain Chairman, while former CEO Jim Corbett is leaving the company. Board member Jan Stern Reed was appointed Lead Independent Director and the Board will engage a search firm to find a permanent CEO, considering internal and external candidates including Mr. Vance.The Company expects preliminary Q3 2025 revenue of approximately $17 million. AVITA secured a waiver from OrbiMed for the Q3 2025 trailing 12-month net revenue covenant and is negotiating revised future covenants. An earnings call is scheduled for November 6, 2025.

#RCEL AVITA Medical Announces CEO Transition

www.stocktitan.net/news/RCEL/avita-medical-...

Pomerantz Law Firm Launches Investigation for AVITA Medical Investors After Stocks Plunge Pomerantz Law Firm is probing potential securities fraud claims against AVITA Medical, Inc., following a significant decline in stock value after the company's troubling financial disclosures.

Pomerantz Law Firm Launches Investigation for AVITA Medical Investors After Stocks Plunge #United_States #New_York #Pomerantz_LLP #AVITA_Medical #RCEL

Pomerantz Law Firm Launches Investigation into AVITA Medical Investors' Claims Pomerantz LLP is probing claims from investors of AVITA Medical regarding potential securities fraud and business malpractice, specifically relating to recent financial disclosures.

Pomerantz Law Firm Launches Investigation into AVITA Medical Investors' Claims #USA #New_York #Pomerantz_LLP #AVITA_Medical #RCEL

Pomerantz Law Firm Investigates Investor Claims for AVITA Medical, Inc. Pomerantz LLP is probing claims on behalf of investors of AVITA Medical, Inc. concerning allegations of securities fraud and other unlawful practices.

Pomerantz Law Firm Investigates Investor Claims for AVITA Medical, Inc. #USA #New_York #Pomerantz #AVITA_Medical #RCEL

Most Searched, Monday September 15, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Sept 15th - #RCEL #CLSK #IBRX #LDI #GPRO #GLUE #RZLV #ONDS #RIG #NAOV #HIVE #RXRX #NAKA #ATYR #WOLF #SBET #RR #QUBT #BITF #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

Pomerantz Law Firm Investigates Claims Against AVITA Medical, Inc. for Investor Protection Pomerantz LLP is conducting an investigation into AVITA Medical, Inc., concerning potential securities fraud and investor claims related to financial disclosures.

Pomerantz Law Firm Investigates Claims Against AVITA Medical, Inc. for Investor Protection #USA #New_York #Pomerantz_LLP #AVITA_Medical #RCEL

5.6 Days Less Hospital Time: AVITA Medical's RECELL System Transforms Burn Care with 36% Faster Recovery Real-world study of 741 burn patients shows RECELL reduces hospital stays by 5.6 days vs traditional grafting, saving $42K per patient. System enables 13 more patients treated annually per bed.

#RCEL Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System

www.stocktitan.net/news/RCEL/real-world-dat...

Leading Wound Care Company AVITA Medical Announces Triple Conference Schedule for September 2025 AVITA Medical executives to participate in Cantor, Morgan Stanley, and Lake Street healthcare conferences this September. CEO Jim Corbett and CFO David O'Toole to host fireside chats and meetings.

#RCEL AVITA Medical Announces September Investor Conference Participation

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Raises US$15M from Australian Investors to Fuel Growth Until Cash Flow Positive US$15M private placement backs AVITA's expansion in wound care therapeutics. Strong institutional support signals market confidence. See growth strategy details.

#RCEL AVITA Medical Successfully Completes Australian Equity Raise

www.stocktitan.net/news/RCEL/avita-medical-...

Avita Medical (RCEL) Q2 Sales Up 21% | The Motley Fool

#RCEL #5da4c98f-459e-4186-84c8-2a39ba5034e4 #data-news

Origin | Interest | Match

Therapeutic Wound Care Leader AVITA Medical Announces Q2 2025 Earnings Date and Conference Call Details Mark your calendar: AVITA Medical's Q2 2025 results coming August 7. Join the earnings call to hear latest developments in therapeutic wound care. Register now.

#RCEL AVITA Medical to Announce Second Quarter 2025 Financial Results

www.stocktitan.net/news/RCEL/avita-medical-...

New Data: Revolutionary RECELL Treatment Cuts Hospital Stays by 35%, Saves Hospitals $300M in Burn Care Latest real-world analysis of 6,300+ patients reveals RECELL's significant impact on burn treatment efficiency. See how this innovation saves hospitals millions. Learn more.

#RCEL AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL

www.stocktitan.net/news/RCEL/avita-medical-...

New data from #AvitaMedical (NASDAQ: #RCEL) highlights the power of regenerative healing!
Their innovative Cohealyx™ system has shown to significantly accelerate wound healing and improve outcomes in skin graft procedures.
#Cohealyx
prismmarketview.com/avita-medica...

AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™ AVITA Medical announced the first clinical publication of Cohealyx, their collagen-based dermal matrix, in the Journal of Surgery. The study demonstrated significantly faster wound bed vascularization and autograft readiness compared to conventional methods, achieving results in 5-10 days versus the typical 2-4 weeks. In a case series at Ohio State University Wexner Medical Center, two patients with complex hand wounds showed excellent outcomes, with one patient achieving vascularization by day 5 and autografting by day 7, while the second patient reached vascularization by day 10 and autografting by day 13. Cohealyx, developed using proprietary TetraPure Technology, contains crosslinked collagen types I and III, supporting optimal cellular migration and rapid revascularization. The accelerated timeline could improve clinical outcomes by enabling earlier wound closure and reducing patient complications.

#RCEL AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today AVITA Medical (NASDAQ: RCEL) is hosting its virtual Acute Wound Care Showcase 2025 on May 13, 2025, at 11:00 a.m. Pacific Time. The event will feature presentations from leading burn and trauma clinicians using AVITA's technologies, alongside patient testimonials about their treatment experiences with the company's solutions.CEO Jim Corbett and SVP of Scientific and Medical Affairs Dr. Katie Bush will present AVITA's integrated approach to acute wound care, highlighting key technologies including RECELL®, Cohealyx™, and PermeaDerm®. The showcase will include a live Q&A session, with registration available through the company's website. A replay will be accessible from May 14 on AVITA Medical's Investor Relations site.

#RCEL AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Reports First Quarter 2025 Financial Results AVITA Medical (NASDAQ: RCEL) reported strong Q1 2025 financial results with commercial revenue of $18.5 million, up 67% year-over-year, and a robust gross profit margin of 84.7%. The company launched two key products: RECELL GO mini™ in February for smaller wounds, and Cohealyx™ in April, expanding their U.S. market opportunity from $455 million to over $3.5 billion. AVITA has completed its commercial transformation from a single-product burn company to a multi-product platform. The company reaffirmed its 2025 guidance, expecting commercial revenue between $100-106 million (55-65% growth), with anticipated free cash flow in H2 2025 and GAAP profitability in Q4. Despite progress, the company reported a net loss of $13.9 million ($0.53 per share), though improved from $18.7 million loss in Q1 2024.

#RCEL AVITA Medical Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/RCEL/avita-medical-...

Game-Changing Wound Care: AVITA's New Cohealyx Shows Superior Healing Results New collagen matrix shows faster healing vs competitors. Complements RECELL System for complete wound care solution. Early trial results promising.

#RCEL AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Boosts Revenue Share to 60% in Strategic PermeaDerm Deal AVITA Medical expands PermeaDerm partnership with Stedical, securing higher revenue share and in-house manufacturing capabilities for wound care matrix technology.

#RCEL AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results AVITA Medical (NASDAQ: RCEL) reported its Q4 and full-year 2024 financial results. Q4 commercial revenue reached $18.4 million, up 30% year-over-year, with an 87.6% gross profit margin. Full-year 2024 revenue was $64.0 million, increasing 29% from 2023, with an 85.8% gross margin.Key developments include FDA clearance for Cohealyx™ and RECELL GO® mini in December 2024. The company provided 2025 revenue guidance of $100-106 million, projecting 55-65% growth. AVITA expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.Q4 net loss was $11.6 million ($0.44 per share), compared to $7.1 million loss in Q4 2023. Full-year 2024 net loss increased to $61.8 million ($2.39 per share). The company ended 2024 with $35.9 million in cash and equivalents.

#RCEL AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Lowers Q4 Guidance, Projects Strong 2025 Growth with $100M Revenue Target AVITA Medical revises Q4 revenue to $18.4M amid slower hospital purchases, but forecasts robust 55-65% growth for 2025 backed by recent product launches and FDA approvals.

#RCEL AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Secures FDA Approval for RECELL GO Mini, Expanding Wound Treatment Portfolio AVITA Medical's newly approved RECELL GO mini targets smaller wound treatments with optimized design, set to launch in Q1 2025 at trauma and burn centers.

#RCEL AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds

www.stocktitan.net/news/RCEL/avita-medical-...

AVITA Medical Secures FDA Clearance for Revolutionary Wound Treatment, Eyeing Triple Market Expansion AVITA Medical's new collagen matrix Cohealyx receives FDA approval, showing superior tissue regeneration in preclinical studies. Launch set for 2025 with major market potential.

#RCEL AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

www.stocktitan.net/news/RCEL/avita-medical-...